探讨益赛普治疗多关节型幼年特发性关节炎的临床疗效与安全性

目的研究探讨益赛普用于治疗多关节型幼年特发性关节炎的临床疗效和安全性。方法随机选出江西省儿童医院多关节型幼年特发性关节炎患儿40例,分为常规治疗组和益赛普组(n=20),常规治疗组使用常规抗风湿药物治疗,益赛普组在常规抗风湿药物的基础上,加用益赛普0.5mg/kg皮下注射治疗,每周2次,连续治疗3个月。比较2组治疗2、4、8和12周时的有效率,红细胞沉降率,C反应蛋白水平和不良反应发生率的差异。结果益赛普组治疗2、4、8和12周时的有效率均高于常规治疗组,红细胞沉降率,C反应蛋白水平和不良反应发生率均明显低于常规治疗组,2组比较差异有统计学意义(P<0.05)。结论益赛普对于多关节型幼年特发性关节炎患者效果显著,安全性高,值得临床广泛推广使用。

Objective To study the clinical efficacy and safety of etanercept for the treatment of juvenile idiopathic arthritis.Methods20 patients in conventional group treated by conventional anti-rheumatic drug for 3 months. 20 patients in etanercept group treated by etanercept twice a week for 3 months, and etantercept group treated by both conventional anti-rheumatic drug.The efficiency,erythrocyte sedimentation rate,C-reactive protein levels and incidence of adverse reactions of 2、4、8and12weeks were compared.Results The effective of 2、4、8and12weeks of experimental group higher,erythrocyte sedimentation rate,C-reactive protein level and incidence of adverse reactions were all signiifcantly lower in the etanercept group than those in the conventionl group.The difference was statistically signiifcance（P＆lt;0.05）.ConclusionThe efifcency of etanercept for treating much better and safer than conventionl treatment.Etanercept is worthy of clinical usage for JIA patients.